证券代码：688130 证券简称：晶华微 公告编号：2023-047 杭州晶华微电子股份有限公司 关于 2023 年前三季度计提资产减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 杭州晶华微电子股份有限公司（以下简称"公司"）于 2023 年 10 月 27 日 召开第一届董事会第二十六次会议、第一届监事会第十八次会议，审议通过了《关 于 2023 年前三季度计提资产减值准备的议案》。现将相关情况公告如下： 一、计提资产减值准备情况概述 根据《企业会计准则》及公司会计政策、会计估计的相关规定，为了真实、 准确地反映公司截至 2023 年 9 月 30 日的财务状况，本着谨慎性原则，公司对截 至 2023 年 9 月 30 日公司及下属子公司的资产进行了减值测试，对可能发生资产 减值损失的相关资产计提减值准备。2023 年前三季度确认的资产减值损失 1,270.60 万元，具体情况如下表： | 序号 | 项目 | 2023 年前三季度计 提金额（万元） | 备注 | | --- | --- | --- | --- ...

索 引 号 bm56000001/2023-00011528 分 类 名 称 关于对杭州晶华微电子股份有限公司及相关人员采取出具警示函措施的决定 我局在现场检查中发现杭州晶华微电子股份有限公司（以下简称晶华微或公司）存在以下问题：一是公司2022年 半年报和三季报中营业收入、利润等相关信息披露不准确；二是公司首次公开发行招股说明书中关于公司及关联方与 缙云县志合电子科技有限公司的资金往来情况披露不准确；三是公司募集资金现金管理审议程序不规范，且审议后存 在现金管理超出审批额度的情况；四是公司财务章未按照公司制度规定使用。 公司上述行为违反了《上市公司信息披露管理办法》（证监会令第182号）第三条、《上市公司监管指引第2号 ——上市公司募集资金管理和使用监管要求》（证监会公告〔2022〕15号）第八条、《上市公司治理准则》（证监会 公告〔2018〕29号）第二条规定，公司董事长吕汉泉、总经理罗伟绍、时任财务总监兼董事会秘书周荣新违反了《上 市公司信息披露管理办法》（证监会令第182号）第四条、第五十一条规定，对相应违规行为承担主要责任。根据 《上市公司信息披露管理办法》（证监会令第182号）第五十二条规定，我局 ...

证券代码：688130 证券简称：晶华微 公告编号：2023-045 杭州晶华微电子股份有限公司 关于公司及相关人员收到浙江证监局警示函的公告 公司上述行为违反了《上市公司信息披露管理办法》（证监会令第 182 号） 第三条、《上市公司监管指引第 2 号--上市公司募集资金管理和使用监管要求》（证 监会公告[2022]15 号）第八条、《上市公司治理准则》（证监会公告[2018] 29 号） 第二条规定，公司董事长吕汉泉、总经理罗伟绍、时任财务总监兼董事会秘书周 荣新违反了《上市公司信息披露管理办法》（证监会令第 182 号）第四条、第五 十一条规定，对相应违规行为承担主要责任。根据《上市公司信息披露管理办法》 （证监会令第 182 号）第五十二条规定，我局决定对晶华微、吕汉泉、罗伟绍、 周荣新分别采取出具警示函的监督管理措施，并记入证券期货市场诚信档案。你 们应认真吸取教训，加强证券法律法规学习，提高公司规范运作水平和信息披露 质量，并于收到本决定书之日起 10 个工作日内向我局提交书面整改报告，杜绝 今后再次发生此类违规行为。 如果对本监督管理措施不服的，可以在收到本决定书之日起 60 日内向中国 证券监 ...

证券代码：688130 证券简称：晶华微 公告编号：2023-044 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号—回购股份》等相关规定，现将公司回购股份进展情况公告如下： 截至 2023 年 9 月 30 日，公司通过集中竞价交易方式已累计回购公司股份 369,168 股，占公司总股本 66,560,000 股的比例为 0.5546%，回购成交的最高价 为 43.64 元/股，最低价为 41.05 元/股，支付的资金总额为人民币 15,760,177.94 元（不含印花税、交易佣金等交易费用）。本次回购股份符合法律法规的规定及 公司的回购股份方案。 杭州晶华微电子股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 截至 2023 年 9 月 30 日，杭州晶华微电子股份有限公司（以下简称"公 司"）通过集中竞价交易方式已累计回购公司股份 369,168 股，占公司总股本 66,560,000 股的比例为 0.5546%，回购 ...

Group 1: Company Overview - The company is Hangzhou Jinghua Microelectronics Co., Ltd., with stock code 688130 and abbreviation Jinghua Micro [1] - The investor relations activity took place on September 22, 2023, in an offline meeting format [2] Group 2: Revenue Breakdown - In the first half of 2023, the revenue from medical health SoC chip products accounted for 57.46%, a year-on-year decrease of 13.33% [3] - Revenue from industrial control and instrumentation chip products represented 41.07%, showing a year-on-year increase of 10.83% [3] - Revenue from intelligent perception SoC chip products was 1.47%, with a significant year-on-year growth of 51.93% [3] Group 3: New Product Launches - In the first half of 2023, the company launched several new products, including high-performance pressure/temperature sensor signal conditioning chips and specialized SoC chips for blood pressure and blood glucose meters [3] - Upcoming products include high-performance eight-electrode body fat scale SoC chips and various other specialized chips, with several high-speed and high-resolution ADC chips expected to be mass-produced by the end of 2023 [3] Group 4: Competitive Advantages - The company's core technological advantages lie in its self-developed high-precision Sigma-Delta ADC SoC technology and low-power, high-interference resistance capabilities in industrial control chips, which are considered advanced domestically [4] - The company also emphasizes integrated solutions and rapid local response to customer feedback [4] Group 5: Client Relationships - Major clients for medical health SoC chips include Xiangshan Weighing Apparatus, Lexin Medical, and Wolai Technology; for industrial control and instrumentation chips, clients include Yuli De, Huashengchang, and Victory Instruments [4] - The company has been actively expanding its market presence and has made progress in collaborations with well-known brands in products like thermometers and uric acid meters [4] Group 6: R&D and Performance Goals - As of June 2023, the company had 124 R&D personnel, reflecting a year-on-year increase of 65.33% [4] - The company has launched a restricted stock incentive plan for 2023, aiming to increase market share and scale, with a target gross margin of 64.14% for the first half of 2023 [4]

证券代码：688130 证券简称：晶华微 公告编号：2023-043 一、回购股份的基本情况 2023 年 8 月 18 日，公司召开了第一届董事会第二十四次会议，审议通过了 《关于以集中竞价交易方式回购股份方案的议案》，同意公司使用超募资金通过 集中竞价交易方式回购公司已经发行的人民币普通股（A 股）股票，并在未来适 宜时机将前述回购股份用于员工持股计划或股权激励。本次回购的资金总额不低 于人民币 1,500 万元且不超过人民币 3,000 万元，回购的价格不超过人民币 60.00 元/股，回购期限自董事会审议通过回购股份方案之日起 12 个月内。具体内容详 见公司分别于 2023 年 8 月 19 日、2023 年 8 月 31 日在上海证券交易所网站 （www.sse.com.cn）披露的《关于以集中竞价交易方式回购股份方案的公告》（公 告编号：2023-035）和《关于以集中竞价交易方式回购公司股份的回购报告书》 （公告编号：2023-042）。 二、首次实施回购股份的情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号—回购股份》等相关规定，现将公司首次回购股份情况公告如 ...

海通证券股份有限公司关于杭州晶华微电子股份有限公司 2023 年持续督导半年度跟踪报告 | 保荐机构名称：海通证券股份有限公司 | 被保荐公司简称：晶华微 | | --- | --- | | 保荐代表人姓名：薛阳、余冬 | 被保荐公司代码：688130 | 重大事项提示 2023 年 1-6 月，晶华微营业收入 6,493.21 万元，较上年同期下降 5.02%；归 属于上市公司股东的净利润为 221.88 万元，归属于上市公司股东的扣除非经常 性损益的净利润为-315.49 万元，分别较去年同期下降 91.53%、114.81%，下滑幅 度较大。公司预计未来在技术研发、人员费用方面仍需保持较大的投入。如果半 导体行业仍处于下行周期，消费景气度缓慢复苏，业务拓展及研发项目进展不及 预期，预计公司未来仍可能出现业绩下滑或亏损的情形。提醒广大投资者对公司 的业绩波动、由盈转亏的情况予以关注。 3 | 项 目 | 工作内容 | | --- | --- | | | 更正，并同步公告了更正后的定期报告；同 | | | 日，晶华微收到上海证券交易所出具的《关于 | | | 对杭州晶华微电子股份有限公司会计差错更 | | ...

标题：关于杭州晶华微电子股份有限公司会计差错更正事项的监管工作函 证券代码：688130 证券简称：晶华微 监管类型：监管工作函 涉及对象：上市公司,中介机构及其相关人员 处分日期：2023-08-30 处理事由：关于杭州晶华微电子股份有限公司会计差错更正事项的监管工作函 ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥17,735,740.08, a decrease of 45.52% compared to the same period last year[5]. - The net profit attributable to shareholders for Q3 2022 was ¥1,882,321.92, down 86.55% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥3,517,857.69, a decline of 125.42% compared to the previous year[5]. - Total operating revenue for the first three quarters of 2022 was CNY 86,097,759.42, a decrease from CNY 133,969,504.28 in the same period of 2021, representing a decline of approximately 35.8%[24]. - Net profit for the first three quarters of 2022 was CNY 28,063,290.03, compared to CNY 62,915,181.87 in 2021, reflecting a decrease of approximately 55.5%[25]. - The total comprehensive income for the third quarter of 2022 was CNY 28,063,290.03, a decrease from CNY 62,915,181.87 in the same period of 2021, representing a decline of approximately 55.5%[26]. - Basic and diluted earnings per share for the third quarter of 2022 were CNY 0.52, down from CNY 1.35 in the previous year, indicating a decrease of about 61.5%[26]. Research and Development - Research and development expenses totaled ¥12,950,712.10, an increase of 87.88% compared to the same period last year, representing 73.02% of operating revenue[6]. - Research and development expenses for the first three quarters of 2022 amounted to CNY 29,395,811.27, significantly higher than CNY 17,658,921.30 in the previous year, marking an increase of about 66.5%[24]. - The company plans to continue focusing on R&D and market expansion strategies to enhance future growth prospects[24]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,337,855,519.88, reflecting an increase of 248.70% from the end of the previous year[6]. - Total assets as of the end of the third quarter of 2022 were CNY 1,337,855,519.88, compared to CNY 383,671,323.60 at the same time in 2021, showing a substantial increase[23]. - Total liabilities for the third quarter of 2022 were CNY 22,779,105.13, up from CNY 20,583,832.52 in the previous year, indicating an increase of approximately 10.7%[22]. - The total equity attributable to shareholders was CNY 1,315,076,414.75, compared to CNY 363,087,491.08 in 2021, representing a significant growth[23]. Cash Flow - The cash flow from operating activities for the year-to-date was -¥16,077,406.01, a decline of 129.28%[6]. - Cash inflow from operating activities for the first three quarters of 2022 was CNY 122,073,454.24, compared to CNY 175,661,977.10 in the same period of 2021, reflecting a decline of approximately 30.5%[28]. - The net cash flow from operating activities for the first three quarters of 2022 was negative CNY 16,077,406.01, contrasting with a positive CNY 54,908,069.56 in the previous year[28]. - Cash inflow from investment activities for the first three quarters of 2022 was CNY 513,268,938.45, compared to CNY 430,200,019.15 in the same period of 2021, showing an increase of about 19.3%[28]. - The net cash flow from investment activities for the first three quarters of 2022 was negative CNY 236,653,445.48, an improvement from negative CNY 272,714,521.85 in the previous year[28]. - Cash inflow from financing activities for the first three quarters of 2022 was CNY 948,428,416.00, significantly higher than CNY 147,600,000.00 in the same period of 2021, indicating an increase of approximately 542.5%[29]. - The net cash flow from financing activities for the first three quarters of 2022 was CNY 918,386,890.10, compared to CNY 145,914,476.00 in the previous year, reflecting a substantial increase of about 528.5%[29]. - The ending balance of cash and cash equivalents as of the end of the third quarter of 2022 was CNY 941,294,899.39, a significant increase from CNY 2,778,212.34 at the end of the previous year[29]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 9,919[12]. - The company’s total number of shares held by the top 10 unrestricted shareholders includes significant holdings by major stakeholders, indicating strong insider confidence[14]. - The company has engaged in strategic placement plans for key employees and executives, enhancing alignment with shareholder interests[14]. Management Changes - The company’s financial director and board secretary resigned on September 30, 2022, with the chairman, Lü Huanquan, appointed to act in these roles temporarily[17]. Other Financial Metrics - The weighted average return on net assets decreased to 0.17%, down 3.93 percentage points year-on-year[6]. - The basic earnings per share for Q3 2022 was ¥0.03, a decrease of 89.29% compared to the same period last year[6]. - The company reported accounts receivable of ¥14,731,990.60 as of September 30, 2022, compared to ¥9,945,626.07 on December 31, 2021, indicating an increase of about 48%[20]. - The company has a total of 239,486,500.00 in trading financial assets as of September 30, 2022, with no previous data provided for comparison[20]. - The company’s prepayments decreased from ¥41,553,288.57 to ¥27,995,957.40, a decline of approximately 33%[20]. - The company has a total of 1,054,748.49 in notes receivable as of September 30, 2022, compared to ¥694,793.00 previously, marking an increase of about 52%[20]. - The company has a total of 389,402.17 in other receivables, up from ¥330,705.60, reflecting an increase of approximately 18%[20].

Financial Performance - The company reported a significant increase in revenue for the first half of 2023, reaching RMB 500 million, representing a 25% year-over-year growth[14]. - The company's operating revenue for the first half of 2023 was ¥64,932,104.88, a decrease of 5.02% compared to the same period last year[19]. - The net profit attributable to shareholders was ¥2,218,788.96, down 91.53% year-on-year[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of ¥3,154,924.02, a decline of 114.81% compared to the previous year[19]. - The gross margin for the first half of 2023 improved to 45%, up from 40% in the same period last year[14]. - Basic and diluted earnings per share were both ¥0.03, down 94.23% from the same period last year[20]. - The company's net profit for the first half of 2023 was CNY 2,218,788.96, a decrease of 91.53% compared to CNY 26,180,968.11 in the same period of 2022[28]. - The company reported a total revenue of 18,910.00 million RMB for the first half of 2023, with a net profit of 3,019.93 million RMB, representing a significant increase from the previous year's 7,351.30 million RMB[60]. Research and Development - The company has invested RMB 50 million in R&D for innovative technologies, focusing on AI integration in its products[14]. - Research and development expenses reached ¥32,864,800, an increase of 99.85% year-on-year, with R&D expenses accounting for 50.61% of operating revenue, up 26.55 percentage points[22]. - The number of R&D personnel increased by 65.33% to 124 by the end of the reporting period[22]. - The company applied for 11 patents and obtained 3 during the reporting period, while it applied for 114 patents and obtained 87 in total[51]. - The company has developed a new calibration technology that significantly improves the performance of its DACs under varying temperature conditions[48]. - The company is actively recruiting high-end R&D talent to support its expansion into new fields[66]. Market Expansion and Strategy - The company is expanding its market presence, targeting new regions in Southeast Asia, aiming for a 10% market share by the end of 2024[14]. - The company has provided a positive outlook for the second half of 2023, projecting a revenue growth of 20% to 30%[14]. - New product launches are expected to contribute an additional 200 million RMB in revenue by the end of the year[130]. - The company is considering strategic acquisitions to bolster its market position, with potential targets identified in the tech sector[130]. - The company is focusing on expanding its market presence in the medical health sector, leveraging its advanced chip technology[35]. Product Development - New product development includes the launch of a next-generation chip expected to enhance performance by 40% over previous models, set to be released in Q4 2023[14]. - The company has developed a high-precision ADC-based signal processing SoC technology for medical health applications, including infrared temperature measurement chips[35]. - The company has developed a high-integration SoC chip for smart health scales, which eliminates the need for additional microcontrollers and display driver chips, providing a comprehensive single-chip solution for health monitoring[38]. - The company launched new products including high-performance blood pressure and blood glucose SoC chips, with Q2 revenue from temperature sensor chips increasing by 319.98% quarter-on-quarter[72]. Financial Management and Risks - The company faces risks related to market competition and reliance on a limited number of products, with over 95% of revenue coming from medical health and industrial control chips[79]. - The company has a risk of accounts receivable bad debts as its accounts receivable balance may increase with business expansion, which could adversely affect cash flow and operational performance if not collected in a timely manner[87]. - The company received a "High-tech Enterprise Certificate" valid for three years, allowing it to enjoy a 15% corporate income tax rate, but any changes to this tax policy could negatively impact future profitability[88]. - The company faces risks of technology and product obsolescence if competitors achieve breakthroughs in multi-chip combinations or if other companies with high-precision ADC technology enter its focus areas[92]. Shareholder Commitments and Governance - The company has committed to not transferring or entrusting the management of its shares for 36 months from the date of its IPO, ensuring stability in shareholding[125]. - The company will report any changes in shareholding through direct or indirect means, adhering to relevant laws and regulations[126]. - The company has established a compliance framework to ensure adherence to regulations regarding share transfers and holdings[128]. - The controlling shareholder and actual controller promise not to interfere in the company's management activities or infringe on the company's interests[136]. Environmental and Social Responsibility - The company promotes an environmental protection and hazardous substance management system throughout its supply chain[122]. - The company has committed to sustainability initiatives, aiming to reduce carbon emissions by 15% over the next three years[130]. - The company is not classified as a key pollutant discharge unit and does not engage in production activities that involve environmental pollution[122].